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BRIEF DEFINITIVE REPORT
        Pulmonary alveolar proteinosis (PAP) is a rare 
disorder of the lung caused by impaired surfac-
tant homeostasis and is clinically characterized 
by the accumulation of lipoproteinaceous ma-
terial within alveolar spaces, often leading to re-
spiratory failure (  1  ). Three forms of PAP have 
been described: congenital, secondary, and ac-
quired. Congenital PAP can result from muta-
tions in genes encoding the surfactant proteins 
B or C, or the common       chain (     c) of the re-
ceptor for GM-CSF (  2  –  6  ). Secondary PAP de-
velops in conditions in which there are reduced 
numbers or functional impairment of pulmonary 
alveolar macrophages, and has been associated 
with the inhalation of inorganic dust (silica) or 
toxic fumes, hematologic malignancies, pharma-
cologic immunosuppression, certain infections, 
and impaired      c expression (  7  –  11  ). Acquired 
PAP is the most common form, usually occur-
ring in adults, and is caused by neutralizing au-
toantibodies to GM-CSF (  12  –  14  ). 
  The importance of GM-CSF in the patho-
genesis of PAP has been confi  rmed in humans 
and mice, wherein GM-CSF signaling is re-
quired for pulmonary alveolar macrophage 
catabolism of surfactant (  12  –  17  ). In addition, 
mice with a targeted disruption of GM-CSF or 
     c genes   developed PAP (  15  –  17  ). Local ex-
pression of GM-CSF in the lungs of GM-CSF  –
  defi  cient mice, or transplantation of bone marrow 
from normal mice into      c-defi  cient mice, cor-
rected the defective metabolism of surfactant 
(  18  –  19  ). Furthermore, administration of GM-
CSF has been effi   cacious in some patients with 
acquired PAP (  20  ). 
  Because the GM-CSFR is composed of a 
cytokine-binding GM-CSFR       chain (GM-
CSFR     ) subunit and the      c subunit (  21,22  ), the-
oretically, defi  ciency of either subunit should 
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  Pulmonary alveolar proteinosis (PAP) is a rare lung disorder in which surfactant-derived 
lipoproteins accumulate excessively within pulmonary alveoli, causing severe respiratory 
distress. The importance of granulocyte/macrophage colony-stimulating factor (GM-CSF) 
in the pathogenesis of PAP has been confi  rmed in humans and mice, wherein GM-CSF 
signaling is required for pulmonary alveolar macrophage catabolism of surfactant. PAP is 
caused by disruption of GM-CSF signaling in these cells, and is usually caused by neutral-
izing autoantibodies to GM-CSF or is secondary to other underlying diseases. Rarely, 
genetic defects in surfactant proteins or the common      chain for the GM-CSF receptor 
(GM-CSFR) are causal. Using a combination of cellular, molecular, and genomic ap-
proaches, we provide the fi  rst evidence that PAP can result from a genetic defi  ciency of 
the GM-CSFR      chain, encoded in the X-chromosome pseudoautosomal region 1. 
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blood count and diff  erential were normal. Worsening respi-
ratory failure was managed intermittently by whole lung saline 
lavage under arteriovenous extracorporeal membrane oxygen-
ator support, but pulmonary function progressively declined. 
Treatment with 20   μ  g/kg GM-CSF per day subcutaneously, 
which may be effi   cacious in some patients with acquired PAP 
(  20  ), was not benefi  cial. Given the absence of surfactant gene 
mutations and anti  –  GM-CSF antibodies, the elevated baseline 
GM-CSF serum levels and the lack of clinical improvement 
with exogenous GM-CSF administration, and no evidence for 
other secondary causes of PAP, the potential for a defect in 
the GM-CSFR was investigated. 
  Lack of GM-CSFR     expression and function 
in the patient  ’  s monocytes 
  To test the hypothesis that the patient had a defect in GM-
CSFR expression, fl  ow cytometry was used to detect GM-
CSFR      and      c on peripheral blood monocytes of the patient, 
as well as her father, mother, and sister. The mother expressed 
high levels of GM-CSFR      on virtually all of her monocytes, 
as demonstrated in   Fig. 1 A   by the single peak of staining on 
her CD14  +   cells, as expected (  23  ).   In contrast, GM-CSFR      
was undetectable on the patient  ’  s monocytes (  Fig. 1 A  ). By 
comparison, the father and sister demonstrated bimodal patterns 
of GM-CSFR      expression on their monocytes (  Fig. 1 A  ), 
have the potential to result in PAP. We provide the fi  rst 
  report that PAP can result from a genetic defi  ciency of the 
GM-CSFR     . 
    RESULTS AND DISCUSSION   
  Case history 
  A 4-yr-old female with Turner syndrome and respiratory in-
suffi   ciency was diagnosed with PAP at age 3. Her past history 
was signifi  cant for respiratory failure caused by respiratory 
syncytial virus pneumonia in the fi  rst month of life, and a di-
agnosis of reactive airways disease. She presented with respi-
ratory distress and hypoxemia, with a   “  crazy paving  ”   pattern 
on chest imaging. Open lung biopsy revealed alveolar pro-
teinaceous material without alveolar epithelial hyperplasia or 
chronic interstitial changes, and bronchoalveolar lavage re-
vealed proteineous material and foamy macrophages, all of 
which are consistent with PAP. Analyses for mutations of 
the genes encoding surfactant proteins B and C and ABCA3 
were negative (performed by the Johns Hopkins DNA Diag-
nostic Laboratory). Her serum GM-CSF concentration mea-
sured by ELISA (performed by the University of Michigan 
Cytokine Reference Laboratory) was 1,573.3 pg/ml (normal = 
0  –  7.8 pg/ml), and anti  –  GM-CSF antibody concentration 
measured by ELISA (performed by the Cleveland Clinic 
Cytokine Biology Laboratory) was 0 ng/ml. Her complete 
    Figure 1.         Absence of GM-CSFR     expression and responsiveness by the PAP patient  ’  s peripheral blood granulocytes.   (A)  CD14 +   peripheral 
blood monocytes from the patient and family members were analyzed for the cell-surface expression of GM-CSFR      by  fl  ow cytometry. The dashed line is 
the isotype-negative control antibody. The patient does not express GM-CSFR      (green). The mother  ’  s monocytes give a single peak for GM-CSFR      ex-
pression (yellow). The father  ’  s and sister  ’  s monocytes give a bimodal pattern of staining for GM-CSFR      expression (blue and red). (B) Up-regulation of 
CD11b expression by stimulation of the patient  ’  s and mother  ’  s peripheral blood granulocytes with GM-CSF was measured by fl  ow cytometry. The histo-
grams demonstrate constitutive expression of CD11b by granulocytes from both the mother and the patient (shaded). Stimulation with 100 ng/ml 
GM-CSF resulted in up-regulation of CD11b on the mother  ’  s granulocytes, but not on the patient  ’  s granulocytes (solid line). The dashed lines are the 
isotype-matched controls. The MFI from the histograms from the mother  ’  s and patient  ’  s granulocytes before and after stimulation with 50 and 100 ng/ml 
GM-CSF were used to calculate the SI, as previously described (reference   25  ). The data were reproducible in duplicate samples and in two 
separate experiments.   JEM VOL. 205, November 24, 2008  2713
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CSF, with a      1.2 SI at 50 ng/ml GMCSF (MFI = 4,294) and 
a      11.6 SI at 100 ng/ml GM-CSF (MFI = 3,841). 
  Absence of GM-CSFR     mRNA transcripts 
by the patient  ’  s leukocytes 
  The patient  ’  s karyotype indicated a 46Xi(Xq) genotype in 
which the Xi chromosome appeared to be of normal length 
and hybridized a probe for the X-chromosome pseudoauto-
somal region 1 (X-PAR1) region (  Fig. 2 A  ).   In contrast, the 
Xq chromosome had a truncated Xp arm and did not hybrid-
ize the X-PAR1 probe. 
  To determine whether the absence of GM-CSFR      protein 
expression was accompanied by impaired expression of GM-
CSFR      mRNA transcripts, RT-PCR was used. For com-
parison, transcripts were also amplifi  ed for      c and the other 
     c-associated receptor molecules (IL-3R      and IL-5R     ), as well 
as mRNA transcripts from genes fl  anking the GM-CSFR     gene 
within the X-PAR1 region (thymic stromal lymphopoietin 
indicating that only a subpopulation of the father  ’  s and the 
sister  ’  s monocytes expressed GM-CSFR    . All subjects expressed 
cell-surface      c (unpublished data), and      c function in the pa-
tient was indicated by the presence of normal numbers of 
peripheral blood eosinophils, which diff  erentiate in response to 
IL-5 signal transduction through the IL-5R      and      c (  24  ). 
  To determine whether the absence of GM-CSFR      ex-
pression by the patient was accompanied by functional unre-
sponsiveness to GM-CSF, GM-CSF  –  induced up-regulation 
of CD11b on granulocytes of the patient and her mother 
were measured by fl  ow cytometry (  Fig. 1 B  ), as previously 
described (  25  ). Constitutive expression of CD11b was greater 
on the mother  ’  s granulocytes (mean fl  uorescence intensity 
[MFI] = 6,337) than the patient  ’  s granulocytes (MFI = 4,347). 
The mother  ’  s granulocytes had a 22.4 stimulation index (SI) 
with 50 ng/ml GM-CSF (MFI = 7,759) and a 34.1 SI with 
100 ng/ml GM-CSF (MFI = 8,498). In contrast, the patient  ’  s 
granulocytes did not up-regulate CD11b in response to GM-
    Figure 2.         Molecular analysis of GM-CSFR    .   (A, left) Karyotype analysis of the PAP patient demonstrating one grossly intact X chromosome (Xi) and 
one short X chromosome that is truncated in the P arm (Xq), characteristic of Turner syndrome. (A, right) FISH analysis of the PAP  patient ’ s  chromosomes 
using a probe specifi  c for the X centromere (teal) and a probe specifi  c for the proximal PAR1 region of the X chromosome (red probe). The PAR1 probe 
hybridizes to the Xi chromosome but not the Xq chromosome. (B, left) Illustration of a subregion of the XPAR1, band p22.33. Highlighted in red is the 
GM-CSFR      gene, which is located between the genes for the TSLPR and the IL-3R     , which is followed by the gene encoding   ASMTL  . (B, right) RT-PCR 
analysis of the genes examined in PAR1 region, as well as genes encoding IL-5R      (Ch. 3p24-p26) and      c (Ch. 22q12.2-13.1). The data were reproducible 
in three out of three experiments.     2714 PULMONARY ALVEOLAR PROTEINOSIS IS CAUSED BY DELETION OF THE GM-CSFR      GENE   | Martinez-Moczygemba et al. 
quire homozygous defects involving both of the GM-CSFR      
alleles. However, because the GM-CSFR      gene is encoded 
in the PAR1 region of the X and Y chromosomes (  26  ), Turner 
syndrome, which is caused by the absence or partial deletion 
of one of the X chromosomes (  27  ), provides the biological cir-
cumstance of nature whereby a defect in one GM-CSFR      
allele could result in the PAP phenotype. 
  The absence of mRNA transcripts for GM-CSFR      and 
IL-3R      indicated that the PAR1 region of the Xi chromo-
some was abnormal, despite the positive hybridization signal 
from the fl  uorescence in situ hybridization (FISH) experiment. 
The presence of mRNA transcripts for TSLPR and ASMTL, 
whose genes fl  ank the genes for GM-CSFR      and IL-3R     , 
respectively, suggested a genomic deletion that aff  ected     1 mb. 
Examination of the 11 coding exons for GM-CSFR      dem-
onstrated deletion of exons 5  –  13, providing a genetic basis 
for the absence of mRNA transcripts and protein for GM-
CSFR     . Because the IL-3R      message was not detected in 
the patient, the genetic deletion aff  ecting GM-CSFR      likely 
extends to the gene encoding IL-3R     . However, impaired 
IL-3 responses do not result in a PAP phenotype in mice (  17  ) 
and have not been associated with PAP in humans. 
  Although the bimodal pattern of GM-CSFR      protein ex-
pression by the patient  ’  s father and sister was not accompanied 
receptor [TSLPR] and acetylserotonin methyltransferase 
[ASMTL]). Results from the patient  ’  s leukocytes were com-
pared with results from her family members and an unrelated 
healthy control (  Fig. 2 B  ). The patient  ’  s family members and the 
control subject each expressed all of the transcripts. In contrast, 
transcripts for GM-CSFR      and IL-3R      were not detected for 
the patient, whereas the other transcripts were detected. These 
data suggested a potential defect in the patient  ’  s X-PAR1 that 
aff  ected both the GM-CSFR      and IL-3R      genes. 
  Deletion of the patient  ’  s GM-CSFR     exons 5  –  13 
  To directly analyze the integrity of the GM-CSFR      gene 
structure, PCR amplifi  cation of each of the 11 exons encoding 
GM-CSFR      (exons 3  –  13) was performed (  Fig. 3  ).   In addition, 
a primer set for exon 8 of the   SMG1   gene on chromosome 16 
was included as an internal PCR control (627 bp). Results with 
the patient  ’  s DNA were compared with those with DNA from 
three control cell lines. Although all 11 coding exons of GM-
CSFR      were detected in each of the controls, only the fi  rst 
two coding exons (exons 3 and 4) of GM-CSFR      were de-
tected in the patient  ’  s DNA; exons 5  –  13 were absent. 
  This is the fi  rst report of PAP resulting from a genetic de-
fi  ciency of GM-CSFR     . Clinical expression of PAP caused 
by a genetic defi  ciency of GM-CSFR      would predictably re-
    Figure 3.         Genomic analysis of GM-CSFR    .   (left) Genomic structure of the GM-CSFR      gene locus depicting the 11 coding exons (black boxes) and intronic 
regions (black line). (right) PCR amplifi  cation of the 11 exons (exons 3  –  13) encoding the GM-CSFR      gene using genomic DNA isolated from the PAP patient  ’  s 
leukocytes. Each GM-CSFR      primer set was designed to generate amplicons of 200  –  350 bp (bottom band), whereas the internal standard (  SMG1  , Ch. 16) was 
627 bp (top band present in all lanes). The fi  rst lane in each group of amplicons is the PAP patient  ’  s DNA sample (P); the remaining three lanes are positive con-
trols. Exons 3 and 4 are present, but exons 5  –  13 are missing from the patient  ’  s genomic DNA. The data were reproducible in three out of three experiments.    JEM VOL. 205, November 24, 2008  2715
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  MATERIALS AND METHODS 
  Study subjects.     The Institutional Review Board of Baylor College of Med-
icine approved this study. All subjects or their legal guardians gave written 
informed consent, and minors gave assent. In addition to the patient, study 
subjects included healthy unrelated controls and the patient  ’  s immediate fam-
ily, which consisted of her mother and father, and a sister, all of whom were 
healthy. Blood was obtained in EDTA tubes from all subjects and was used 
immediately for analyses. In brief, the red blood cells were hypotonically 
lysed and the leukocytes were resuspended in PBS containing 2% FCS. 
  Flow cytometry.     GM-CSFR      cell-surface expression on peripheral blood 
monocytes was analyzed on a fl  ow cytometer (model XL; Beckman Coulter). 
Monocytes were identifi  ed using mouse mAb anti  –  human CD14  –  Alexa 
Fluor 488 (M5E2; BD). GM-CSFR      expression on monocytes was detected 
using mouse IgG1 mAb anti  –  human GM-CSFR      (4H1; Santa Cruz Bio-
technology, Inc.) and rat mAb anti  –  mouse IgG1-PE. Background was 
determined using an isotype-matched negative control mAb (MOPC-21; BD). 
Data were analyzed using Summit software (Dako). 
  GM-CSF up-regulation of CD11b expression.     Peripheral blood granu-
locytes were analyzed by fl  ow cytometry for GM-CSF up-regulation of 
CD11b expression, as previously described (  25  ), using mouse mAb anti  –  hu-
man CD11b (ICRF44; BD). In brief, freshly isolated white blood cells were 
either unstimulated or stimulated in vitro with 50  –  100 ng/ml human GM-
CSF for 30 min. Cells were labeled with anti-CD11b  –  PE antibodies and 
gated on the granulocyte population, and CD11b expression was measured 
by fl  ow cytometry. The GM-CSF  –  induced CD11b SI on granulocytes was 
calculated by taking the MFI of CD11b on GM-CSF  –  stimulated granulo-
cytes minus the MFI of CD11b on unstimulated granulocytes, divided by 
the MFI of CD11b on unstimulated granulocytes, multiplied by 100, as pre-
viously described (  25  ). Data were plotted using Excel software (Microsoft). 
  Karyotype and FISH analysis.     High-resolution G-banded metaphase 
chromosome analysis was performed on the patient  ’  s peripheral blood lym-
phocytes. FISH was performed to detect the proximal region of the X-PAR1 
using bacterial artifi  cial chromosome (BAC) probe RP11-74L17, which hy-
bridizes at 1.781  –  1.929 mb on Xp22.3. X chromosomes were identifi  ed 
  using a BAC probe specifi  c for the X centromere. Miniprep BAC DNA 
(100 ng) was labeled with Spectrum Orange-dUTP or Spectrum Green-dUTP 
(Vysis) and used as probes for FISH analysis, as previously described (  29  ). 
  RT-PCR.     Total RNA was extracted from peripheral blood leukocytes 
from the patient, family members, and an unrelated healthy control using the 
RNeasy Mini kit (QIAGEN). 3   μ  g of total RNA was reverse transcribed 
with Oligo dT primers using the SuperScript III First-Strand Synthesis Sys-
tem for RT-PCR (Invitrogen). 1   μ  l of the cDNA reaction was used to am-
plify each cytokine receptor and control gene with specifi  c primers, for 35 
cycles. PCR amplifi  cation conditions were as follows: 5 min at 95  °  C for 
1 cycle; 45 s at 94  °  C for 35 cycles; 1 min at 60  °  C for 1 cycle; 2 min at 72  °  C 
for 1 cycle; and 12 min at 70  °  C for a fi  nal cycle (GeneAmp 9700 PCR Sys-
tem; Applied Biosystems). PCR products were analyzed in a 1% (wt/vol) 
agarose gel containing ethidum bromide and were visualized by fl  uores-
cence. The PAP patient is missing mRNA transcripts for GM-CSFR      and 
IL-3R     . Primer sequences are listed in Table S1 (available at http://www
.jem.org/cgi/content/full/jem.20080759/DC1). 
  Amplifi  cation of the GM-CSFR     gene.     Primer sets fl  anking each of the 
11 coding exons (exons 3  –  13) of the GM-CSFR      (  CSF2RA  ) gene were 
individually amplifi  ed. A primer set for exon 8 of the   SMG1   gene on chro-
mosome 16 was used as an internal PCR standard. Each GM-CSFR      exon 
primer set was designed to generate amplicons of 200  –  489 bp, whereas the 
internal standard was 627 bp. Amplifi  cation of the patient  ’  s DNA and DNA 
from three normal control cell lines was performed with Multiplex mix (QIA-
GEN) using standard PCR conditions. A positive and a negative control for 
the PCR process were also performed using primers fl  anking exon 10 of the 
by a clinical phenotype, this raises the possibility that both the 
father and sister are carriers of a PAR1 partial deletion. If so, 
then such a deletion resides on the paternal X-PAR1, and not 
on the Y-PAR1, and would be consistent with the patient  ’  s 
Xi being of paternal origin. Alternatively, the patient  ’  s Xi-
PAR1 deletion may have occurred de novo in the context of 
recombination and genomic rearrangement that resulted in the 
Turner genotype. 
  The PAR1 is essential for meiotic pairing and recombina-
tion of sex chromosomes (  26, 28  ). Although all genes within 
the PAR1 escape X inactivation and are therefore candidates 
for haploinsuffi   ciency disorders, the only previously known 
disease gene within the PAR1 is the short-stature homeobox 
(  28  ). Although the PAR1 has a high frequency of recombi-
nation, the subregion encoding the GM-CSFR      gene appar-
ently has a relatively low level of recombination (  28  ). The 
frequency of mutations in GM-CSFR      that impair physio-
logical responses to GM-CSF is unknown, but is likely to be 
rare even in large populations because the prevalence of PAP 
is low. However, the potential importance of GM-CSF re-
sponsiveness for granulocyte and pulmonary alveolar macro-
phage function leaves open the possibility that some degree 
of immune dysfunction could occur in the context of partial 
unresponsiveness to GM-CSF. Indeed, the recent demonstra-
tion of an impaired ability of granulocytes to respond to GM-
CSF in autoimmune PAP (  25  ) was confi  rmed in our patient 
by the inability of her granulocytes to up-regulate expression 
of CD11b after GM-CSF stimulation. Moreover, the imme-
diate adjacency of the genes for TSLPR, GM-CSFR     , and 
IL-3R     , all of which encode for receptors of relevance to al-
lergic infl  ammation, also raises the intriguing possibility that 
  mutations within this PAR1 region may have implications for 
the pathophysiology of allergic disorders. 
  The importance of GM-CSF signaling in PAP is under-
scored by the experimental observation that mice with a targeted 
disruption of GM-CSF or      c genes developed PAP (  15  –  17  ). 
In addition, local expression of GM-CSF in the lungs of GM-
CSF  –  defi  cient mice, or transplantation of bone marrow from 
normal mice into      c-defi  cient mice, corrected the defective 
metabolism of surfactant (  18  –  19  ). GM-CSFR       –  defi  cient mice 
have not been reported. 
  Diagnosing PAP caused by a genetic defi  ciency of GM-
CSFR      has important therapeutic implications because, the-
oretically, bone marrow reconstitution from a healthy donor 
should result in leukocytes that express the GM-CSFR      and 
thereby a cure for the impaired surfactant homeostasis that 
underlies PAP, especially because such a strategy has been suc-
cessfully demonstrated in mice with      c defi  ciency (  19  ). Our 
patient underwent bone marrow reconstitution with an 
HLA-matched unrelated donor but died from a respiratory 
infection 4 wk after transplant, before recovery of immune 
competency. Nonetheless, the ability to screen for GM-CSFR      
defi  ciency by fl  ow cytometry provides a convenient test for 
evaluating infants with PAP not explained by other causes of 
GM-CSF unresponsiveness, and can be confi  rmed by molec-
ular methods. 2716 PULMONARY ALVEOLAR PROTEINOSIS IS CAUSED BY DELETION OF THE GM-CSFR      GENE   | Martinez-Moczygemba et al. 
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